"While we are disappointed that we will not be working with Pfizer for the commercialization of Indiplon, Neurocrine is fully committed and prepared to develop and commercialize this product," said Gary Lyons, the company's president and CEO.
"With the clinical, regulatory and commercial investment we have received from Pfizer coupled with our experience in conducting the Indiplon clinical development program, we are well-positioned to complete development of this product to secure FDA approval, and we anticipate a seamless transition of responsibility," he added.- Loading Comments...
- Loading Comments...
Featured Photo Galleries
Connect with TheStreet
 |
 |
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,197.09 | 1,087.23 | 2,149.02 | 34.46 |
Oil *
75.93
|
|
DOWN
94.17
|
DOWN
11.28
|
DOWN
17.88
|
DOWN
0.28
|
10 Yr
3.45%
SPDR Gold
108.21
|
|
-0.92%
|
-1.03%
|
-0.83%
|
-0.81%
|
Data delayed 20 minutes |
